Sfoglia per RIVISTA
ESMO OPEN
Collezione AOU San Luigi di Orbassano

  

Items : 10

MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database. in ESMO open / ESMO Open. 2024 Sep;9(9):103680. doi: 10.1016/j.esmoop.2024.103680. Epub 2024 Aug 29.

2024
ASL Asti
AOU San Luigi di Orbassano

Baldini E; Di Micco C; Banini M; Calvetti L; Leone F; Carta A; Pignataro D; Pozzessere D; Muscolino P; Bria E; Citarella F; Pilotto S; Cortinovis D; Gariazzo E; Pelizzari G; Roca E; Galetta D; Sini C; Delmonte A; Bulotta A; Occhipinti M; Minuti G; Cappuzzo F; Reale ML; Passiglia F; Favaretto A; Malapelle U; Novello S; Pasello G; et alii...

A cross-sectional study evaluating the exercise discussion with oncologist during cancer consultation: the CONNECT study. in ESMO open / ESMO Open. 2024 Jul;9(7):103624. doi: 10.1016/j.esmoop.2024.103624. Epub 2024 Jun 28.

2024
AOU San Luigi di Orbassano

Avancini A; Giannarelli D; Borsati A; Carnio S; Cantale O; Nepote A; Mangiapane F; Bafunno D; Galetta D; Longo V; Tregnago D; Trestini I; Belluomini L; Sposito M; Insolda J; Schena F; Milella M; Novello S; Pilotto S;

Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe. in ESMO open / ESMO Open. 2023 Oct;8(5):101628. doi: 10.1016/j.esmoop.2023.101628. Epub 2023 Sep 14.

2023
AOU San Luigi di Orbassano

Hofman P; Calabrese F; Kern I; Adam J; Alarcão A; Alborelli I; Anton NT; Arndt A; Avdalyan A; Barberis M; Bégueret H; Bisig B; Blons H; Boström P; Brcic L; Bubanovic G; Buisson A; Caliò A; Cannone M; Carvalho L; Caumont C; Cayre A; Chalabreysse L; Chenard MP; Conde E; Copin MC; Côté JF; D'Haene N; Dai HY; et alii...

Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities. in ESMO open / ESMO Open. 2022 Feb;7(1):100308. doi: 10.1016/j.esmoop.2021.100308. Epub 2021 Dec 21.

2022
ASL Torino 4
AOU San Luigi di Orbassano

Milella M; Pastorino U; Rolli L; Infante M; Capella C; Bria E; Pilotto S; Fontanini G; Mastracci L; Volante M; Mangogna A; Grillo F; Mafficini A; Ciaparrone C; Sabella G; Taormina S; Garzone G; Ali G; Simbolo M; Centonze G; Scarpa A; Milione M;

Subgroup analyses in randomized phase III trials of systemic treatments in patients with advanced solid tumours: a systematic review of trials published between 2017 and 2020. in ESMO open / ESMO Open. 2022 Dec;7(6):100593. doi: 10.1016/j.esmoop.2022.100593. Epub 2022 Oct 12.

2022
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Di Maio M; Mariniello A; Perrone F; Reale ML; Gargiulo P; Di Liello R; Gamba T; Caglio A; Bungaro M; Audisio M; Paratore C; Zichi C;

Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma. in ESMO open / ESMO Open. 2022 Apr;7(2):100422. doi: 10.1016/j.esmoop.2022.100422. Epub 2022 Mar 7.

2022
ASL Torino 4
AOU San Luigi di Orbassano

Sigala S; Tiberio GAM; Terzolo M; Canu L; Turla A; Gianoncelli A; Ferrari VD; Zamparini M; Abate A; Ambrosini R; Cosentini D; Grisanti S; Laganà M; Berruti A;

Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study. in ESMO open / ESMO Open. 2021 Oct;6(5):100246. doi: 10.1016/j.esmoop.2021.100246. Epub 2021 Aug 17.

2021
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Di Maio M; Pietrantonio F; Di Bartolomeo M; Corallo S; Morano F; Ratti M; Berenato R; Zaniboni A; Clavarezza M; Murialdo R; Ritorto G; Tampellini M; Amatu A; Smiroldo V; Antoniotti C; Lonardi S; Leone AG; Raimondi A; Fucà G;

New emerging targets in cancer immunotherapy: the role of VISTA. in ESMO open / ESMO Open. 2020 Jun;4(Suppl 3):e000683. doi: 10.1136/esmoopen-2020-000683.

2020
AOU San Luigi di Orbassano

Novello S; Bironzo P; Tagliamento M;

Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy. in ESMO open / ESMO Open. 2020 Jan;5(1):e000567. doi: 10.1136/esmoopen-2019-000567.

2020
AOU San Luigi di Orbassano

Lee P; Wolff K; Alexandris E; Oton AB; Zimmermann AH; Orlov SV; Cuyun Carter G; Brustugun OT; Gans S; Kim JH; Kalofonos H; Iglesias Docampo L; Thomas M; Reck M; Gautschi O; Scagliotti GV; Garon EB; Stefaniak VJ; Socinski MA; Pérol M;

Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: an individual patient data (IPD) analysis. in ESMO open / ESMO Open. 2018 Nov 1;3(6):e000327. doi: 10.1136/esmoopen-2018-000327. eCollection 2018.

2018
AOU San Luigi di Orbassano

Garassino MC; Kawaguchi T; Gregorc V; Rulli E; Ando M; Marsoni S; Isa SI; Novello S; Farina G; Barni S; Torri V; Cinquini M;